Morning Glory Sciences– Author –
-
Rethinking Cancer Atlases and “Microbial Signatures”: History, Importance, and the Latest Update (Part 1 | Intro for Beginners)
This post explains, in plain language, why pan-cancer (comprehensive) analyses and atlas databases matter in oncology, and how the concept of microbial signatures fits into that bigger picture. As a short preface to the series, we also t... -
China Biopharma Deals, 2019–2025: Part 4 — Regulatory History, Why It Surged, Adoption Checklist, and Outlook
This final part pulls together the structural drivers — regulation, capital formation, clinical infrastructure — and turns them into a practical adoption checklist. We close with our own view of what comes next and where value will accru... -
China Biopharma Deals, 2019–2025: Part 3 — Respiratory/Immunology, CNS, Infectious and More
Beyond oncology and metabolic, partnering has matured in respiratory and immunology, CNS, and infectious diseases. Beyond oncology and metabolic, partnering has matured in respiratory and immunology, CNS, and infectious diseases. This ar... -
China Biopharma Deals, 2019–2025: Part 2 — Obesity and Metabolic (Oral GLP-1, Dual Agonists)
Obesity and type 2 diabetes are massive in clinical burden and market size. Obesity and type 2 diabetes are massive in clinical burden and market size. China-origin programs are notable in oral GLP-1 design and in practical, scalable man... -
Latest Science “Aging “News : Does Education Slow Brain Aging? A Plain-Language Guide to a Massive 33-Country Study
“Higher education means you won’t get dementia”—it sounds reassuring, but the science is more nuanced. “Higher education means you won’t get dementia”—it sounds reassuring, but the science is more nuanced. This article explains, in clear... -
China Biopharma Deals, 2019–2025: Part 1 — Oncology (ADC, Bispecifics, IO, Cell Therapy)
Oncology is the tip of the spear for China-origin innovation in global partnering. Oncology is the tip of the spear for China-origin innovation in global partnering. This article gives you a bird’s-eye view of the major deals, then goes ... -
How Respiratory Viral Infections May Alter Metastatic Risk in Breast Cancer: Latest Evidence and Practical Guidance
Respiratory viral infections may silently reshape metastatic risk in breast cancer survivors. Recent epidemiology and mechanistic studies converge on a practical question: what should clinicians change tomorrow morning? Here is the evide... -
The “Dark Side” of NK Cells in Cancer Immunotherapy Part 2: Therapeutic Strategies and Future Outlook
In Part 1, we reviewed mechanisms by which NK cells contribute to resistance against immune checkpoint blockade (ICB). In this follow-up article (Part 2), we discuss the clinical implications, potential strategies, and future directions ... -
The “Dark Side” of NK Cells in Cancer Immunotherapy Part 1: Immunosuppressive Roles and Resistance Mechanisms
Natural killer (NK) cells have long been recognized as frontline effectors of tumor surveillance. However, recent studies reveal that their role within the tumor microenvironment (TME) is far more complex. NK cells are increasingly impli... -
Obesity Drug Updates Part 2: Pricing and Reimbursement of GLP-1 Obesity Drugs Across Japan, the U.S., and Europe
Introduction: Innovation Means Nothing Without Access GLP-1 obesity drugs have created explosive demand worldwide, but the critical bottleneck is cost. With prices reaching hundreds of dollars per month and long-term treatment required, ... -
Claudin18.2 ADC Development Part 4: Global Development Landscape and Future Outlook
Claudin18.2 (CLDN18.2)-directed ADCs are rapidly emerging as a cornerstone in the treatment of advanced gastric and gastroesophageal junction (GEJ) ca Claudin18.2 (CLDN18.2)-directed ADCs are rapidly emerging as a cornerstone in the trea... -
Obesity Drug Updates Part 1: Novo’s Layoff and the Next Phase of GLP-1 Obesity Drugs – Innovation and Pipeline Competition
Introduction: Novo’s Layoff as a Symbol of Industry Transition In September 2025, Novo Nordisk announced a massive layoff of about 9,000 employees, roughly 12% of its global workforce. The decision comes amid intensified competition in t... -
Claudin18.2 ADC Development Part 3: Comparative Analysis of SHR-A1904 and IBI343
Two phase 1 trials—SHR-A1904 and IBI343—have propelled the clinical development of CLDN18.2-directed ADCs. This article provides a head-to-head compar Two phase 1 trials—SHR-A1904 and IBI343—have propelled the clinical development of CLD... -
Claudin18.2 ADC Development Part 2: Phase 1 Results and Clinical Features of IBI343
In this article, we summarize the phase 1 trial of IBI343, reported in Nature Medicine (July 2025), focusing on its structural innovations, safety, efficacy, and position within the landscape of Claudin18.2-targeted ADCs. Drug Profile: M... -
Enteric neuron–gastric cancer organoids expose lipid-metabolic Achilles’ heels — Strengths and limits of organoids for drug discovery, and what comes next
In a nutshell: Genome-wide CRISPR screens in patient-derived gastric cancer organoids uncovered strong dependencies on fatty-acid biosynthesis (ACC/ACACA) and cholesterol biosynthesis (LSS). Co-culture with enteric neurons (ENS) rewires ... -
Catchup News: HER2 ADC Special Report Part 2｜IP Strategies, Global Competition, and the Road Ahead
In Part 1 of our feature, we explored Enhertu’s groundbreaking pharmacological profile and its role in launching the second ADC boom. In this concluding part, we shift focus to intellectual property strategies, patent lifespans, and the ... -
Claudin18.2 ADC Development Part 1: Phase 1 Results and Clinical Significance of SHR-A1904
Antibody–drug conjugates (ADCs) targeting Claudin18.2 (CLDN18.2) have gained increasing attention as a novel therapeutic approach for advanced gastric and gastroesophageal junction (GEJ) cancers. Here, we summarize the phase 1 trial resu... -
Catchup News: HER2 ADC Special Report Part 1｜The Rise of Enhertu and Pharmacological Differentiation Driving the Second ADC Boom
Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Among them, HER2-targeted ADCs have undergo... -
Biotech Exits: What is SPAC, and How Exit Strategies are Evolving
In recent years, “exit” has become one of the most critical milestones for startups. In the biotech industry, traditional IPOs and M&As have been the main paths, but SPACs (Special Purpose Acquisition Companies) emerged as an alterna... -
Claudin18.2 ADC Development Part 0: Series Introduction
This series provides an in-depth review of the current landscape of Claudin18.2 (CLDN18.2)-targeted antibody–drug conjugates (ADCs) in gastric and gastroesophageal junction (GEJ) cancers. Structured into five parts, it covers pivotal cli...
